MLTX vs. RCUS, PTGX, KROS, DICE, DVAX, GMTX, AGIO, SNDX, ZNTL, and TARO
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Arcus Biosciences (RCUS), Protagonist Therapeutics (PTGX), Keros Therapeutics (KROS), DICE Therapeutics (DICE), Dynavax Technologies (DVAX), Gemini Therapeutics (GMTX), Agios Pharmaceuticals (AGIO), Syndax Pharmaceuticals (SNDX), Zentalis Pharmaceuticals (ZNTL), and Taro Pharmaceutical Industries (TARO). These companies are all part of the "pharmaceutical preparations" industry.
MoonLake Immunotherapeutics vs.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.
MoonLake Immunotherapeutics has higher earnings, but lower revenue than Arcus Biosciences. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Arcus Biosciences received 153 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 83.33% of users gave MoonLake Immunotherapeutics an outperform vote while only 63.16% of users gave Arcus Biosciences an outperform vote.
76.1% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 73.0% of Arcus Biosciences shares are held by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 13.8% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
MoonLake Immunotherapeutics presently has a consensus target price of $25.29, indicating a potential downside of 8.22%. Arcus Biosciences has a consensus target price of $41.44, indicating a potential upside of 104.16%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
In the previous week, Arcus Biosciences had 11 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 15 mentions for Arcus Biosciences and 4 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.34 beat Arcus Biosciences' score of 0.11 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -233.41%. Arcus Biosciences' return on equity of -41.22% beat MoonLake Immunotherapeutics' return on equity.
Summary
MoonLake Immunotherapeutics beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
